摘要
目的探讨血清降钙素原(procalcitonin,PCT)在评估老年社区获得性肺炎(community-acquired pneumonia,CAP)病情严重程度及预后中的临床应用价值。方法选择2015年6月至2017年4月我院收治的120例老年肺炎患者作为观察组,按严重程度(CURB-65分级标准)分为低危组(0~1分),中危组(2分),高危组(3~5分)三组,同时选择72例非感染性疾病患者作为对照组,对比分析治疗前后血清PCT及C-反应蛋白(C-reactive protein,CRP)水平;观察组患者根据治疗前PCT水平分为两组,即PCT≤10 ng/m L组和PCT>10 ng/m L组,分析两组患者的预后差异。结果治疗前观察组患者PCT(9.24±2.05 ng/m L)及CRP(48.14±5.38 mg/L)水平均高于对照组(0.95±0.52 ng/m L,4.46±0.68 mg/L),差异有统计学意义(P<0.05);观察组中,治疗前低危组PCT水平(4.33±1.48 ng/m L)低于中危组(8.72±2.58 ng/m L)及高危组(19.42±3.88ng/m L),差异具有统计学意义(P<0.05),中危组PCT水平低于高危组,差异具有统计学意义(P<0.05),治疗后低危组和中危组PCT水平显著下降,差异有统计学意义(P<0.05);治疗前低危组、中危组、高危组的CRP水平无统计学差异(P>0.05),治疗后CRP水平较治疗前相比差异无统计学意义(P>0.05);治疗前PCT≤10 ng/m L组的痊愈率明显高于PCT>10 ng/m L组(P<0.01)。结论血清PCT可用于老年肺炎的诊断,血清PCT水平与老年肺炎患者病情严重程度密切相关,也可用于患者疗效判断和预后评估。
Objective To study the clinical value of serum procalcitonin on estimation of severityand prognosis of elderly patients with community-acquired pneumonia （CAP）. Methods 120 cases of patients with elderly pneumonia treated in our hospital from June 2015 to April 2017 were selected asthe observation group, and divided into the low- risk group （ 0-1 score）, moderate- risk group （ 2 scores ） and high- risk group （ 3- 5 scores ） according to the severity（ CURB-65 ）. At thesame time ,72 cases of patients with non-infectious disease were selected as the control group, and the serumPCT and C-reactive protein （CRP） levels before and after treatment were compared and analyzed. The observation patients were separated into two groups according to their PCT level before treatment： the PCT -〈 10 ng/mL group and PCT 〉 10 ng/mL group. Then the difference of the prognosis was analyzed. Results The PCT and CRP levels in the observation group before treatment were higher than those in the control group with statistical significance E （ 9.24 ± 2.05 ng/mL）, （48.14 .5.38 mg/L） vs（O. 95 -20.52 ng/mL）, （4.46 ±0.68 rag/L） ] ,P 〈0.05. In the observation patients,the level of PCT in low-risk group（4.33 - 1.48 ng / mL） was lower than that of the moderate-risk group （8.72 ± 2.58 ng/mL） and the high-risk group （19.42 ± 3.88 ng/mL）, the difference was statistically significant（ P 〈 0.05 ）. The level of PCT in moderate-risk group was lower than that in high-risk group, the difference was statistica.lly significant（ P 〈 0.05 ）. The PCT levels in the low-risk group and moderate-risk group significantlydecreased after treatment （P 〈 0.05 ）. There was no significant difference in CRP level among low- risk group, moderate- risk group and high- risk group before treatment （ P 〉 0.05 ）, and there was no significantdifference compared with that before treatment（ P 〉 0.05 ）. The curative ratio in PCT -〈 10 ng/ mL group before treatment is higher thanthat in P
出处
《标记免疫分析与临床》
CAS
2017年第11期1209-1211,1215,共4页
Labeled Immunoassays and Clinical Medicine
